Our Businesses

Generics

Pre-eminent Leadership

Committed to uncompromised quality in products and services, Jacobson is a leading supplier of generic drugs to both public and private sectors in Hong Kong that outperforms the other following multinational players.

With its balanced and diversified product portfolio, the Group serves both the public and private sectors by its extensive market penetration covering substantially all of the public hospitals and clinics, private hospitals and registered pharmacies, private doctors and retail outlets in Hong Kong.

Leveraging our significant market presence and in-depth industry knowledge, we also work along with our overseas business partners to represent their products in Hong Kong, Macau, China and the Asia Pacific region for brand and market development.

Our large and growing portfolio allows us to compete with some of the key players in the industry as well as helps extend our presence into new markets.

  • BALANCED AND DIVERSIFIED GENERICS PORTFOLIO
  • EXTENSIVE MARKET COVERAGE
  • SERVING SUBSTANTIALLY ALL HOSPITALS AND OUT-PATIENT CLINICS
  • LEADERSHIP IN A HOST OF HIGH GROWTH THERAPEUTIC CLASSES

Proprietary Medicines

Widely recognized brands of strong heritage

Jacobson also holds a proprietary medicine portfolio comprises notable brands like Po Chai Pills (保濟丸), Ho Chai Kung Tji Thung San (何濟公止痛退熱散), Tong Tai Chung Woodlok Oil (唐太宗活絡油), Flying Eagle Woodlok Oil (飛鷹活絡油), Saplingtan (十靈丹), Shiling Oil (十靈油), Col-gan Tablet (傷風克), Contractubex Scar Gel (秀碧除疤膏) and Doan's Ointment (兜安氏藥膏). All these household brands carry a high recognition amongst the consumers,enjoying strong andcomplementary marketpositions in Hong Kong and the Asia Pacific region.

A leader of its class in the Group’s propriety medicines is Po Chai Pills which possesses 120 years of tradition and has been rated as the most recognized brand by consumers in Hong Kong in the gastrointestinal category of proprietary Chinese medicines.

The brand name of Ho Chai Kung was originated in the 1930’s and has also been widely recognized with a strong market position in the analgesics (pain-killer) category in Hong Kong, China and South-East Asia markets.

Cultivating strong brands is a key factor of success in the market. With relentless commitment towards further establishing its proprietary medicines portfolio, the Group continues to enhance brand management, marketing and sales of our proprietary medicines business and expansion of its sales platform in Hong Kong, China, and Asia Pacific regions.

  • BRANDS WITH HIGH
    REGIONAL RECOGNITION
    FOR GEOGRAPHIC
    MARKET PENETRATION

  • PO CHAI PILLS
    AS LEADING
    BRAND OF CATEGORY

Biosimilars,
Genomics and
Clinical
Diagnostics

With a swift-to-market strategy through in-licensing and direct investment on biopharmaceutical projects, the Group is poised to target the biosimilars market which has witnessed robust growth over the years.

Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases. However, biologics are driving the rising cost of healthcare, and this may restrict access to life-saving treatment. A biosimilar is an approved follow-on medicine with comparable quality, safety and efficacy of an existing biologic upon its patent expiry, offering a more affordable option to patients.

The advancement in genomics has helped redefine personalized medicine. The Group has been collaborating with the world’s leading provider of genomic-based diagnostic tests to help early-stage breast cancer patients optimize treatment decisions and outcomes throughout the cancer patient journey, such as by identifying the small percentage of patients with early-stage disease who will truly benefit from chemotherapy, thus eliminating the “one-size-fits-all” therapeutic approach to cancer that often results in either over- or under-treatment.

The Group also expands its technological and commercial collaboration into the clinical diagnostics arena, with on-going projects such as an innovative non-invasive technology in prostate cancer screening and the pre-clinical diagnosis for early Alzheimer detection. The growing rate of many chronic diseases has increased the demand for personalized medicine, expanding geriatric population base and increasing patient awareness towards disease diagnosis.

Regional Presence

Hub for Regional Coverage and Collaboration

In line with our vision and development, we continuously expand our footprints in certain strategic markets in Asia, entering into collaborative framework agreements with key partners in the region. Business development in the form of forging strategic partnership with local players in certain emerging markets is actively pursued.

Leveraging on its regional platform, Jacobson is well poised to collaborate strategically with reputable manufacturers globally through in-licensing, technology transfer or representation of finished branded products for expanding market presence in the Asia Pacific region such as China, Korea, Japan, Taiwan, Singapore, Malaysia, Cambodia, Myanmar, Thailand and Vietnam.

Located at the hub of the region, Jacobson is well positioned to provide a one-stop service and support to our partners across the Asian markets.